Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

Yoshinobu Aisa, Takehiko Mori, Masumi Kudo, Tomoko Yashima, Sakiko Kondo, Akihiro Yokoyama, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Goals: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. Patients and methods: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. Results: Only two of 18 patients (11.1%) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7%; P=0.001). Conclusion: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.

Original languageEnglish
Pages (from-to)266-269
Number of pages4
JournalSupportive Care in Cancer
Volume13
Issue number4
DOIs
Publication statusPublished - 2005 Apr

Fingerprint

Stomatitis
Cryotherapy
Melphalan
Hematopoietic Stem Cells
Transplants
Ice
National Cancer Institute (U.S.)
Transplant Recipients
Radiation
Drug Therapy
Water

Keywords

  • Hematopoietic stem cell transplant
  • High-dose melphalan
  • Oral cryotherapy
  • Stomatitis

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. / Aisa, Yoshinobu; Mori, Takehiko; Kudo, Masumi; Yashima, Tomoko; Kondo, Sakiko; Yokoyama, Akihiro; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Supportive Care in Cancer, Vol. 13, No. 4, 04.2005, p. 266-269.

Research output: Contribution to journalArticle

Aisa, Yoshinobu ; Mori, Takehiko ; Kudo, Masumi ; Yashima, Tomoko ; Kondo, Sakiko ; Yokoyama, Akihiro ; Ikeda, Yasuo ; Okamoto, Shinichiro. / Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 4. pp. 266-269.
@article{637e7e415f5940c0841762e2137e97a0,
title = "Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients",
abstract = "Goals: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. Patients and methods: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. Results: Only two of 18 patients (11.1{\%}) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7{\%}; P=0.001). Conclusion: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.",
keywords = "Hematopoietic stem cell transplant, High-dose melphalan, Oral cryotherapy, Stomatitis",
author = "Yoshinobu Aisa and Takehiko Mori and Masumi Kudo and Tomoko Yashima and Sakiko Kondo and Akihiro Yokoyama and Yasuo Ikeda and Shinichiro Okamoto",
year = "2005",
month = "4",
doi = "10.1007/s00520-004-0726-y",
language = "English",
volume = "13",
pages = "266--269",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

AU - Aisa, Yoshinobu

AU - Mori, Takehiko

AU - Kudo, Masumi

AU - Yashima, Tomoko

AU - Kondo, Sakiko

AU - Yokoyama, Akihiro

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2005/4

Y1 - 2005/4

N2 - Goals: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. Patients and methods: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. Results: Only two of 18 patients (11.1%) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7%; P=0.001). Conclusion: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.

AB - Goals: The purpose of this study was to evaluate the efficacy of oral cryotherapy to prevent high-dose melphalan-induced stomatitis. Patients and methods: Eighteen consecutive recipients of allogeneic hematopoietic stem cell transplant conditioned with high-dose melphalan (140 mg/m2) in combination with fludarabine alone or with fludarabine and additional chemotherapy or radiation were enrolled. The severity of stomatitis was graded according to the National Cancer Institute Common Toxicity Criteria. Patients were kept on oral cryotherapy using ice chips and ice-cold water shortly before, during, and for additional 90 min after completion of melphalan administration. Results: Only two of 18 patients (11.1%) developed grade 2 or 3 stomatitis while six of seven patients in the historical control developed it (85.7%; P=0.001). Conclusion: These results suggested that oral cryotherapy could effectively prevent stomatitis caused by high-dose melphalan, and we recommend that it should be incorporated into the conditioning regimen with high-dose melphalan.

KW - Hematopoietic stem cell transplant

KW - High-dose melphalan

KW - Oral cryotherapy

KW - Stomatitis

UR - http://www.scopus.com/inward/record.url?scp=17744374486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744374486&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0726-y

DO - 10.1007/s00520-004-0726-y

M3 - Article

C2 - 15668755

AN - SCOPUS:17744374486

VL - 13

SP - 266

EP - 269

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -